Libmeldy

Atidarsagene autotemcel, the active ingredient in Libmeldy, is a gene therapy presented as an autologous CD34+ cell suspension for intravenous infusion. It is indicated for the treatment of metachromatic leukodystrophy, a lysosomal storage disorder, in pediatric and adult patients with confirmed ARSA deficiency.

GNH USA supplies Libmeldy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialized clinics worldwide, ensuring strict quality control, traceability and provision of all required regulatory documentation for efficient and safe import and clinical application.

Libmeldy is a gene therapy indicated for metachromatic leukodystrophy, a lysosomal storage disease affecting the central nervous system.

Late‑infantile MLD: delays loss of motor function and prolongs survival. Juvenile MLD: stabilises neurological decline and improves cognitive outcomes. Adult MLD: reduces disease progression and supports functional independence.

Libmeldy may cause a range of adverse reactions following infusion of genetically modified cells.

Common Side Effects: - Fever or chills - Nausea or vomiting - Fatigue or malaise - Infusion‑related reactions (e.g., rash, hypotension) - Transient cytopenias (low blood counts) - Mild liver enzyme elevations

Serious or Rare Side Effects: - Graft failure or poor engraftment - Insertional oncogenesis leading to malignancy - Severe opportunistic infections - Autoimmune phenomena (e.g., hemolytic anemia) - Neurotoxicity or worsening neurological status - Life‑threatening allergic reactions

Before administering Libmeldy, clinicians should consider several safety measures.

Patient selection: confirm ARSA deficiency and appropriate disease stage before therapy. Pre‑conditioning: appropriate chemotherapy may be required to facilitate stem‑cell engraftment. Infection risk: monitor for opportunistic infections during immune reconstitution. Long‑term monitoring: assess neurological function and enzyme levels regularly. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Libmeldy can interact with other therapies that affect immune function or stem‑cell engraftment.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may impair stem‑cell engraftment. - Live vaccines: increased risk of infection; should be avoided. - Strong immunosuppressants: may exacerbate infection risk.

Moderate Interactions (Monitor Closely): - Antiviral prophylaxis agents: may require dose adjustment. - Growth‑factor support (e.g., G‑CSF): monitor blood counts. - Other investigational gene therapies: assess for overlapping vector immunity.